DiscoveryBioMed, Inc. Awarded Phase 2 SBIR Grant

NIH Grants Company $750k to Continue Their Innovative Research

News courtesy of Discovery BioMed release

DiscoveryBioMed, Inc. recently announced that it received a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the discovery and development of small molecules to alleviate multiple chronic human diseases including cystic fibrosis (CF), hypertension and chronic kidney diseases with hypertension. The company has adapted a known electrical bioassay method to be high-throughput screening friendly, a necessary solution to bring the bioassay to the molecular target endogenous to the apical cell membrane of polarized renal and respiratory epithelia. The molecular target in play for this drug discovery program is an epithelial ion channel that is the rate-limiting step for the handling of salt in the distal portions of the kidney and in the respiratory tract. At the end of Phase 2, Discovery BioMed anticipates having pre-clinical animal data and, possibly, proof-of-concept efficacy data in animals and in humans to show to potential out-license partners.

TechConnect News note: Discovery BioMed was selected to present at TechConnect Ventures 2009-Houston. To view their Executive Summary, visit:

↑ Back to TechConnect News™

Annual Meeting

TechConnect World 2015
National Harbor, MD, June 29 thru July 1, 2020